Meeting
2023 ASCO Annual Meeting
Concordance among the three commercially available PD-L1 assays for esophageal squamous cell carcinoma.
Authors
Lizhen Wang
Roche (China) Holding Ltd., Shanghai, China
Lizhen Wang , Jhe-Cyuan Guo , Chien Huai Chuang , Grace Cao , Stacey Huang , Jia Liu , Tony Guo , Tsung-Che Wu , Shuang Li , Jing Lin , Hsi-Yu King , Jun Cai , Wenjun Yang , Qingyuan Liu , Simon Allen , Yifan Wang , Jingyu Zhang , Chih-Hung Hsu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4058)
DOI
10.1200/JCO.2023.41.16_suppl.4058
Abstract #
4058
Poster Bd #
379
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
First Author: Mathilde Cancel
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Microsatellite instability (MSI) in patients with gastric cancer (GC) and correlation with PD-L1 expression.
First Author: Henian Sun
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Benefit of immune checkpoint inhibitors (ICI) for patients with advanced esophageal squamous cell carcinoma and low PD-L1 expression: A systematic review and meta-analysis.
First Author: Mario Machado Lopes
Poster
2023 ASCO Annual Meeting
Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.
First Author: Nourhan El Ahmar